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l-3,4-Dihydroxyphenylalanine (l-DOPA) remains the primary pharmacological agent for 
the symptomatic treatment of Parkinson’s disease (PD). However, the development of 
l-DOPA-induced dyskinesia (LID) limits the long-term use of l-DOPA for PD patients. 
Some data have reported that adenosine A2A receptor (A2AR) antagonists prevented LID 
in animal model of PD. However, the mechanism in which adenosine A2AR blockade 
alleviates the symptoms of LID has not been fully clarified. Here, we determined to 
knock out (KO) the gene of A2AR and explored the possible underlying mechanisms 
implicated in development of LID in a mouse model of PD. A2AR gene KO mice were 
unilaterally injected into the striatum with 6-hydroxydopamine (6-OHDA) in order to 
damage dopamine neurons on one side of the brain. 6-OHDA-lesioned mice were then 
injected once daily for 21 days with l-DOPA. Abnormal involuntary movements (AIMs) 
were evaluated on days 3, 8, 13, and 18 after l-DOPA administration, and real-time 
polymerase chain reaction and immunohistochemistry for glutamic acid decarboxylase 
(GAD) 65 and GAD67 were performed. We found that A2AR gene KO was effective in 
reducing AIM scores and accompanied with decrease of striatal GAD67, rather than 
GAD65. These results demonstrated that the possible mechanism involved in alleviation 
of AIM symptoms by A2AR gene KO might be through reducing the expression of striatal 
GAD67.
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inTrODUcTiOn
Parkinson’s disease (PD) is a common progressive neurodegenerative disorder characterized by brad-
ykinesia, rigidity, resting tremor, and postural instability (1). The pathogenesis of PD has not been 
completely delineated, but believed to involve a multifactorial etiology including age-related, genetic, 
and environmental factors (2). Long-term therapy with l-3,4-dihydroxyphenylalanine (l-DOPA), 
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the most common and effective symptomatic treatment for PD, 
often leads to the severe side effects such as dystonic, choreic, and 
ballistic movements, collectively referred to as l-DOPA-induced 
dyskinesia (LID) (3). Approximately 10% of patients have experi-
enced LID in the first year of dopamine replacement therapy, and 
the incidence of LID is up to nearly 95% in patients who survive 
15 years from diagnosis (4, 5). LID severely affects quality of life 
and leads to enormous social and economic burden to patients 
and their caregivers. Current effective treatment strategy for LID 
is mainly by a reduction in drug dose, which has a rebound of 
parkinsonian symptoms (6). Thus, an effective and satisfying 
management of LID is still urgently needed of PD therapy.
Basal ganglia is an important subcortical center for the regula-
tion of voluntary movement, whose output pathways include the 
direct striatonigral–striatoentopeduncular gamma aminobutyric 
acid (GABA) pathway and the indirect striatopallidal GABA 
pathway (7). The unbalanced activities of basal ganglia output 
pathways were thought to be correlated with the development of 
the dyskinesias. Especially dysfunction of the indirect pathway 
can indirectly cause alterations in the pallidothalamic output 
(8). Adenosine A2A receptor (A2AR), which acts in opposition 
to dopamine D2 receptor (D2R) and colocalized with D2R in 
indirect striatopallidal GABAergic pathway, offers a unique 
opportunity to modulate basal ganglia function mediated by 
dopamine (9). Pharmacological antagonists of A2AR prevented 
dopamine-induced motor complications and significantly 
increased l-DOPA efficacy in rats and primates when adminis-
tered with l-DOPA (10, 11). On the basis of recent preclinical 
studies performed using A2AR antagonists as well as the good 
curative effect obtained, A2AR antagonists appear to be a promis-
ing non-dopaminergic therapy for PD (12–14). Unfortunately, 
the mechanism by which adenosine A2AR blockade alleviates the 
symptoms of LID has not been fully clarified.
As the neurotransmitter of striatal projection neurons, GABA 
might play a role in LID (15). Studies have shown that the chronic 
systemic administration of l-DOPA to 6-OHDA-lesioned rats 
increased GABA release in the substantia nigra (16, 17) and 
GABA-synthesizing enzyme glutamic acid decarboxylase (GAD) 
gene expression in striatonigral neurons (18–20). GAD, the 
rate-limiting enzyme responsible for the production of GABA, is 
classified into two major types: GAD65 and GAD67. GAD65 and 
GAD67 are derived from two different genes, which are located 
on chromosome 10 and chromosome 2, respectively (21). The 
reason why GAD67 and GAD65 are so named is that their appar-
ent molecular weights are 65,400 and 66,600  Da, respectively. 
GAD65 is largely present as an inactive apoenzyme (GAD without 
bound cofactor; apoGAD), thus providing a reservoir of inactive 
GAD that can be drawn on when additional GABA synthesis 
is required, while GAD67 is by and large present as a perma-
nently active pyridoxal phosphate-bound holoenzyme (22–24). 
A regional difference exists in the relative expression of these two 
isoforms of GAD. Comparative in situ hybridization in rat brain 
showed high relative levels of GAD67 mRNA were expressed in 
brain regions such as medial septal nucleus, neocortex, inferior 
colliculus, and cerebellum, while GAD65 mRNA was particularly 
abundant in regions such as olfactory tubercle, zona incerta, and 
substantia nigra (25). In the matter of subcellular distributions, 
GAD65 was preferentially found in nerve terminals, while 
GAD67 was located more equally in the cytoplasm as well as in 
nerve terminals, which suggested that GAD67 might be involved 
in the synthesis of GABA for general metabolic activity, whereas 
GAD65 was involved in synaptic transmission (26). Several lines 
of evidence have revealed that LID in experimental models of 
PD was associated with an overexpression of GAD mRNA 
on striatal output neurons (19, 20, 27–29). Between these two 
neurotransmitter-related mRNAs, GAD67 mRNA has mainly 
been the focus of the study and considered to be positively cor-
related with the dyskinesia. The upregulation of GAD67 mRNA 
following the dopamine-denervated lesion was paralleled by 
increased GAD enzyme activity and extracellular levels of GABA 
in the striatum (28, 30). In addition, the antagonistic adenosine 
A2A and D2R interaction occurring in striatopallidal GABAergic 
pathways also regulates GABAergic neurotransmission in these 
areas (31). When adenosine levels rise in the basal ganglia, the 
activation of A2AR abolished dopamine D2 agonist-induced 
inhibition of GABA release (7, 32–34). Whereas A2AR antagonists 
could potentiate this inhibitory effect and reduced the release of 
GABA (31).
Based on these findings, it can be hypothesized that there is 
an association between adenosine A2AR and GAD. Thus, the aim 
of our study is to explore the effect of adenosine A2AR knockout 
(KO) on the expression of GAD67 and GAD65 in striatal neurons 
in LID.
aniMals anD MeThODs
animals
The A2AR KO mice were purchased from the Jackson Laboratory 
and were established on the Balb/c strain background. Wild-type 
(WT) Balb/c mice were purchased from Slac Laboratory Animal 
Company. KO mice were crossed with WT mice to get the het-
erozygous mice, and then, the heterozygous mice were crossed 
with each other to get the KO mice and WT mice. A2AR homozy-
gous KO mice and WT Balb/c mice were bred at the Laboratory 
Animal Centre of Wenzhou Medical University. Experiments 
were conducted on 24 WT and 24 adenosine A2AR gene KO adult 
male mice weighing 25–30 g on arrival, which was further ran-
domly assigned to the following three experimental groups (eight 
per group): the sham group, the PD group, and the LID group. 
All of the mice were housed under a 12-h light:12-h dark cycle, 
temperature 22.0 ±  2.0°C, and relative humidity of 55 ±  10%. 
Food and water were available ad libitum. All procedures associ-
ated with the care of animals were performed according to the 
National Institutes of Health for the care and use of laboratory 
animals (NIH publication No 80-23) and were approved by the 
Animal Ethics Committee of Wenzhou Medical University. All 
efforts were made to reduce the number of animals used.
induction of Parkinsonism and liD
Unilateral 6-OHDA lesions were performed according to the pre-
vious standard procedure (35, 36). Briefly, mice were anesthetized 
with chloral hydrate (0.3 g/kg, i.p.) and placed in the stereotaxic 
frame. Two microliters of 6-OHDA (1 mg 6-OHDA dissolved in 
200 μl 0.05% ascorbic acid) were stereotaxically injected into the 
FigUre 1 | Time course of abnormal involuntary movement (aiM) 
scores development with l-3,4-dihydroxyphenylalanine (l-DOPa) plus 
benserazide exposure. AIM scores in wild-type (WT)-l-3,4-
dihydroxyphenylalanine-induced dyskinesia (LID) group, A2A−/− LID group on 
days 3, 8, 13, and 18 after l-DOPA administration. *P < 0.05, compared with 
WT-LID group.
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left striatum (relative to bregma and dura): anterior–posterior: 
−0.5 mm, medial–lateral: +2.0 mm, and dorsoventral: −2.8 mm 
with a Hamilton syringe at a speed of 0.4  μl/min. The sham-
operated mice were similarly treated but received physiological 
saline containing 0.2% ascorbic acid instead of 6-OHDA. After 
injections, mice were kept warm (37°C) until they recovered from 
surgery. Three weeks later, the lesioned mice were evaluated by 
rotation test over 30  min after apomorphine (0.5  mg/kg, i.p.) 
administration, and only severely lesioned animals were selected 
for the next experiment (more than 7 full-body turns/min toward 
the side of the unlesioned side). One day after apomorphine test, 
they were then treated with 25 mg/kg l-DOPA and 6.25 mg/kg 
benserazide (i.p. injection/day) for 3 weeks in order to induce a 
mouse model of dyskinesia.
abnormal involuntary Movement 
(aiM) ratings
Abnormal involuntary movements were evaluated on days 3, 8, 
13, and 18 after l-DOPA administration. After the daily injection 
of l-DOPA, the mice were observed individually for 1 min every 
20 min from 20 to 120 min. At each observation time point, the 
AIMs were classified into three subtypes: axial, limb, and oro-
lingual movements as detailed by Lindenbach et  al. (37). Each 
subtype was scored on a severity scale from 0 to 4 (0 = absent, 
1 = present during less than half of the observation time, 2 = pre-
sent for more than half of the observation time, 3 = present for 
1 min but suppressible by external stimuli, and 4 = present all the 
time but not suppressible by external stimuli). For each mouse, 
the total AIM score for each test session was calculated by sum-
ming the three individual dyskinesia scores.
real-time Polymerase chain reaction
The expression levels of GAD65 and GAD67 were measured 
using real-time polymerase chain reaction. Total RNA was 
extracted from the brain striatum of lesioned hemisphere using 
TriZol (Ambion, USA) and reverse transcribed into cDNA using 
the PrimeScript RT Reagent Kit (Takara, Japan). Quantitative 
polymerase chain reaction was performed in a 25-μl reac-
tion mixture using SYBR Premix Ex Taq™ II (Takara, Japan) 
according to the manufacturer’s instructions. The amplification 
of the housekeeping gene β-GAPDH cDNA was used as an 
internal control. Forward and reverse primers, respectively, 
used for PCR were 5′-CACCTGCGACCAAAAACCC-3′ 
and 5′-AGATGACCATGCGGAAGAAG-3′ for GAD65, and 
5′-CTCCCTTCTTCAGGCTCTCCC-3′ and 5′-GGTCTTGGGG 
TCTCTACGGTTC-3′ for GAD67.
histological and immunohistochemical 
analyses
In terms of histological and immunohistochemical analysis, we 
extract the whole striatum section (both dorsal and ventral) to 
stain. Experimental mice were anesthetized with 10% chloral 
hydrate (0.3  g/kg, i.p.), and perfused transcardially with saline 
and then fixed by perfusion with 4% paraformaldehyde. Brains 
were removed and prepared as 4-μm paraffin-embedded sections. 
Endogenous peroxidase was blocked with 3% H2O2, and tissue was 
treated overnight at 4°C with primary antibodies:mouse mono-
clonal antibody against GAD67 (1:1,000 dilution, Millipore), 
or rabbit polyclonal antibody against GAD65 (1:1,000 dilution, 
Sigma). Sections were then incubated with the secondary anti-
body for 1 h at room temperature, followed by coloration with 
3,3-diaminobenzidine (DAB, Sigma, Germany) and hematoxylin 
counterstaining. The sections were washed with 0.01 mol/l PBS 
between each step. We analyzed the average integral optical 
density (IOD) of cells positively stained with GAD65 or GAD67 
and calculated the mean values and SDs. Three regions of interest 
were randomly chosen from each section for quantification by 
using Image-Pro Plus 6.0.
statistical analysis
Measurement data were expressed as mean ± SD. Significance of 
the difference between two groups was analyzed using two-tailed 
Student’s t-test. Multiple groups were compared using one-way 
analysis of variance (ANOVA) and followed by LSD post  hoc 
comparisons when appropriate. All statistical analyses were per-
formed with SPSS 20.0 software (IBM, Armonk, NY, USA) and 
GraphPad Prism 6.05 (GraphPad, La Jolla, CA, USA). P < 0.05 
was considered statistically significant.
resUlTs
effects of adenosine a2ar gene KO on the 
Behavior of Mice with liD
In this study, in the process of induction of 6-OHDA-lesioned 
PD mice, the survival rate and the rate of successful lesions are 
about 80 and 50%, respectively. PD rats treated with l-DOPA 
for 18 days developed a progressive increase in LID as indicated 
by AIM score. Median AIM score of WT-LID increased from 
59.63 ± 8.12 on day 3 to 79.88 ± 5.46 on day 18 (n = 8, Ftime = 12.32, 
P <  0.05 compared with day 3, ANOVA and followed by LSD 
post hoc analysis, Figure 1). After KO of adenosine A2AR gene, 
similar trend of AIM score was found, namely, increased from 
FigUre 2 | effects of adenosine a2a receptor (a2ar) gene knockout (KO) on striatal gaD65 and gaD67 expression. (a) Representative images of GAD65 
immunohistochemistry studies in sham, 6-OHDA-lesioned wild-type (WT), or A2AR gene KO mice treated with vehicle or pulsatile l-3,4-dihydroxyphenylalanine 
(l-DOPA) (25 mg/kg, bid: 9:00 a.m.; 5:00 p.m.). (B) Representative images of GAD67 immunohistochemistry studies in sham, 6-OHDA-lesioned WT, or A2AR gene 
KO mice treated with vehicle or pulsatile l-DOPA (25 mg/kg, bid: 9:00 a.m.; 5:00 p.m.). (c) Statistical analysis for integral optical density (IOD) of GAD65. There was 
no significant difference of GAD65 between WT-l-3,4-dihydroxyphenylalanine-induced dyskinesia (LID) and A2A−/− LID groups, n = 8 per group. *P < 0.05, **P < 0.01 
vs. sham. ⬥⬥P < 0.01 vs. Parkinson’s disease (PD). (D) Statistical analysis for IOD of GAD67. The IOD of GAD67 in WT-LID group was significantly higher than 
A2A−/− LID group, n = 8 per group. **P < 0.01 vs. sham. ⬥⬥P < 0.01 vs. PD. ▲▲P < 0.01 vs. LID.
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44.75 ± 7.61 on day 3 to 64.00 ± 7.80 on day 13, and 60.5 ± 6.5 
on day 18 (n = 8, Ftime = 0.523, P > 0.05 compared with day 13, 
ANOVA and followed by LSD post hoc analysis, Figure 1). It is 
remarkable that AIM score of A2A−/− LID group was obviously 
lower compared to the WT-LID group at the same time point 
(n = 8, P < 0.05, two-tailed Student’s t-test, Figure 1).
effects of adenosine a2ar gene KO on 
gaD65 and gaD67 expression in the 
striatum of Mice with liD
Immunohistochemistry
Immunohistochemical studies showed significant increase 
of GAD65 (sham: 0.063  ±  0.007; PD: 0.081  ±  0.007; LID: 
0.168 ± 0.013) and GAD67 (sham: 0.012 ± 0.001; PD: 0.055 ± 0.006; 
LID: 0.109 ±  0.010) in WT-LID compared to WT-sham and 
WT-PD groups (n  =  4, P  <  0.05, two-tailed Student’s t-test, 
Figure 2). In A2AR gene KO groups, treatment with l-DOPA (LID 
group) can significantly increase the IOD of both GAD65 (sham: 
0.056 ± 0.004; PD: 0.092 ± 0.015; LID: 0.149 ± 0.013) and GAD67 
(sham: 0.014 ±  0.005; PD: 0.036 ±  0.007; LID: 0.072 ±  0.013) 
(n = 4, Ftreatment = 5.324, P < 0.05 vs. PD group or sham group, 
ANOVA and followed by LSD post hoc analysis, Figure 2). When 
comparing the IOD of GAD67, WT-LID group was significantly 
higher than A2A−/− LID group (n = 4, P < 0.01, two-tailed Student’s 
t-test, Figure 2). However, there was no significant difference of 
GAD65 between WT-LID and A2A−/− LID groups (n = 4, P > 0.05, 
two-tailed Student’s t-test, Figure 2).
Real-time Polymerase Chain Reaction
Real-time polymerase chain reaction showed significant 
increase of GAD65 (sham: 0.93 ±  0.05; PD: 1.58 ±  0.15; LID: 
2.12 ± 0.18) and GAD67 (sham: 0.98 ± 0.03; PD: 1.35 ± 0.10; 
LID: 2.03  ±  0.26) mRNA expression in WT-LID compared 
to WT-sham and WT-PD groups (n =  4, P <  0.05, two-tailed 
Student’s t-test, Figure  3). In A2AR gene KO groups, treatment 
with l-DOPA (LID group) can significantly increase the mRNA 
expression of both GAD65 (sham: 1.05 ± 0.07; PD: 1.25 ± 0.11; 
LID: 1.55 ± 0.57) and GAD67 (sham: 0.85 ± 0.05; PD: 1.12 ± 0.12; 
LID: 1.63 ± 0.10) (n = 4, Ftreatment = 11.23, P < 0.05 vs. PD group 
or sham group, ANOVA and followed by LSD post hoc analysis, 
Figure 2). In 6-OHDA lesioned mice treated with l-DOPA, stri-
atal GAD67 mRNA level was significant lower in the A2A−/− LID 
group compared to WT-LID group (n = 4, P < 0.01, two-tailed 
Student’s t-test, Figure 3). However, when comparing the mRNA 
expression of GAD65, the WT-PD group shows a milder increase 
FigUre 3 | effects of adenosine a2a receptor gene knockout on striatal gaD65 and gaD67 mrna expression. (a) There was no significant difference of 
striatal GAD65 mRNA expression between wild-type (WT)-l-3,4-dihydroxyphenylalanine-induced dyskinesia (LID) and A2A−/− LID groups, n = 8 per group. P > 0.05 
compared with A2A−/− LID group. (B) In 6-OHDA-lesioned mice treated with l-3,4-dihydroxyphenylalanine (l-DOPA), striatal GAD67 mRNA level was significant lower 
in the A2A−/− LID group compared to WT-LID group, n = 8 per group. **P < 0.01 compared with A2A−/− LID group.
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compared to A2A−/− PD group and a decrease in A2A−/− LID group 
in contrast to WT-LID. Nevertheless, there was no significant dif-
ference between two groups (n = 4, P > 0.05, two-tailed Student’s 
t-test, Figure 3).
DiscUssiOn
The present study showed that A2AR gene KO reduced the sever-
ity of LID induced by subchronic l-DOPA in 6-OHDA-lesioned 
mice. A2AR gene KO also reversed the effects of l-DOPA on 
GAD67, but not GAD65 expression in striatal projection neu-
rons. These data supported the hypothesis that deletion of A2AR 
gene alleviated LID via downregulating the expression of striatal 
GAD67.
l-3,4-Dihydroxyphenylalanine remains the primary pharma-
cological agent for the symptomatic treatment of PD. However, 
the development of LID limits the long-term use of l-DOPA 
for PD patients. Recent studies showed that A2AR might play an 
important role in the treatment of LID. Thus, in the present study, 
we determined to KO the gene of A2AR and explored the possible 
underlying mechanisms implicated in development of LID in a 
mouse model of PD.
Previous experimental data have showed that chronic l-DOPA 
treatment significantly increased the level of striatal A2AR 
mRNA in normal monkeys exhibiting marked dyskinesia (38). 
Consistent with this, two recent positron emission tomography 
studies have reported that there were higher levels of A2AR bind-
ing in dyskinetic PD patients compared with non-dyskinesia (39, 
40). Some data have reported that A2AR antagonists prevented 
dopamine-induced motor complications in 6-OHDA-lesioned 
rodent animal model of PD (41) and MPTP-treated primates 
(42). These findings provided overwhelming evidence for the 
assumption that blockade of A2ARs on striatopallidal neurons 
of the indirect pathway may have a beneficial antidyskinetic 
potentiality (43).
As previous A2AR antagonists have been certified for their 
properties of inability to worsen established dyskinesia, we found 
that A2AR gene KO was effective in reducing AIM scores. The peak 
of AIM scores appeared beforehand at day 12 in A2A−/− LID group, 
while WT-LID group was still in the process of developing LID. 
And severity of dyskinesia was significantly alleviated by A2AR 
KO during the whole observation period. These findings again 
provided directly strong evidence for the beneficial antidyskinetic 
potentiality of A2AR deficiency against the development of LID, 
which well verified the above assumption.
As described above, the A2AR gene-deficient mice induced to 
dyskinesia by administration of l-DOPA (25 mg/kg) presented a 
relatively low AIM score in our study. However, the mechanism 
of the alleviation of dyskinesia symptoms by A2AR KO is unclear. 
Possible pathway might include D2R, since A2AR is largely co-
expressed with D2R and antagonizes D2R-mediated behavioral 
and neurochemical effects in the basal ganglia through a form 
of antagonistic A2A–D2 heteromeric receptor complexes in the 
striatum where it modulates dopaminergic neurons activity (44). 
Moreover, enhanced GABA release was found in dyskinetic rats 
(16), and studies have showed that A2AR could affect the release 
of GABA via D2R. For instance, blockade of striatal A2AR reduced 
the dopamine D2R-mediated GABA release, whereas activation of 
A2AR promoted the release of GABA (45). However, what should 
also be noted is that the regulation of striatopallidal neurons 
mediated by A2AR does not completely ascribe to antagonistic 
A2AR–D2R heterodimer since the stimulatory effect of adenosine 
A2AR antagonists on motor activity is still present in D2 KO mice 
(46, 47). Hence, endogenous adenosine via A2AR at least partly 
regulates the activity of striatopallidal transmission in a dopamine 
D2R-independent manner and that other mechanisms that can 
also affect GABA release in the striatum might be of importance 
upon dopamine depletion (13, 48).
Glutamic acid decarboxylase, as the rate-limiting enzyme 
responsible for the production of GABA, was reasonably taken 
into our consideration. Our finding that unilateral degeneration 
of nigrostriatal dopaminergic neurons increased striatal GAD65 
and GAD67 gene expression was consistent with a previous study 
(49), which has been thought involved in the activation of the 
indirect striatopallidal GABA pathway (50). GABA neurons in 
the striatum appear as medium-sized spiny projection neurons, 
medium-sized aspiny interneurons, and large-sized aspiny 
interneurons, all of which have synaptic connections from 
dopaminergic nerve terminals. GAD-immunoreactive GABA 
neurons in the striatum constitute most of the medium-sized 
6Yin et al. A2AR KO Prevents LID
Frontiers in Neurology | www.frontiersin.org March 2017 | Volume 8 | Article 88
spiny neurons with efferent projections (51–53). Dopamine, as is 
well known, can inhibit downstream GABA release in the globus 
pallidus by binding to Gi-coupled D2Rs located in the striatum. 
The dopamine-denervated lesion increased extracellular levels 
of GABA and simultaneously upregulated GAD65 and GAD67 
gene expression in the striatum. The increase in GAD67 gene 
expression is restricted to a small population (approximately 10% 
of all striatal GABA neurons) of medium-sized projection neu-
rons (18, 54). Chronic intermittent administration of l-DOPA 
(20  mg/kg) to mice with 6-OHDA lesion induced dyskinesia, 
thereby leading to further increases in GAD65 and GAD67 gene 
expression. The progressive increase in GAD gene expression 
was paralleled by an increase in GABA synthesis in striatopallidal 
neurons (20). Thus, the massive increase of GAD induced by 
chronic intermittent l-DOPA (20 mg/kg) administration in the 
damaged striatum appeared to be related to dopamine neuron 
degeneration.
As found in the present study, A2A−/− LID group was accom-
panied with a significant decrease in GAD67, which is involved 
in general metabolic processes activity and is considered an 
index of GABA neuron activity (55). However, it did not produce 
significant modifications in striatal GAD65. The effects of A2AR 
KO were more pronounced on GAD67 than on GAD65, suggest-
ing that GAD65 might not play a similar role as GAD67 on the 
sensitized behavioral responses to l-DOPA (20). It seems that 
different mechanisms might be involved in the regulation of these 
two GAD genes in striatopallidal neurons (49). GABA is synthe-
sized by two distinct enzymes GAD67 and GAD65 that differ 
in their cellular localization, functional properties, and cofactor 
requirements. GAD67 exists as both homo- and heterodimers in 
both soluble and membrane-bound forms, primarily within the 
cell soma but also to a limited degree in terminals (56). During 
the development, GAD67, but not GAD65, deleted homozygous 
mice die immediately after birth and had only less than 10% of 
normal brain GABA levels (57). In the adult, it is critical for main-
taining intracellular GABA reserves for metabolic activity and 
other functions such as synaptogenesis and protection against 
neuronal injury, rather than for vesicular release. GAD67 protein 
contents can be influenced by the level of intraneuronal GABA, 
and this occurrence was not associated with a change in GAD67 
mRNA levels (58, 59). Also, there appears to be isoform-specific 
physiological feedback, in that GAD67 mRNA and protein levels, 
rather than GAD65, were increased in cortical neurons after sen-
sory learning (60, 61). This is the reason, at least in part, GAD67 
contributed to alleviating LID of A2AR KO mice.
In summary, the present study indicated that A2AR KO had 
an important effect on the expression of striatal GAD67, which 
might affect the production of GABA and thus further alleviate 
dyskinesia.
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